Core Insights - Jade Biosciences, Inc. is focused on developing therapies for autoimmune diseases and has outlined its strategic priorities for 2026, including key milestones ahead of the J.P. Morgan Healthcare Conference [1][2] Key Program Updates - JADE101 is a fully human monoclonal antibody targeting APRIL, currently in Phase 1 trials, showing high binding affinity and engineered for extended half-life, aiming for patient-friendly dosing [3][4] - JADE201, an anti-BAFF-R monoclonal antibody, is set to enter first-in-human studies in rheumatoid arthritis patients in Q2 2026, with interim data expected in 2027 [5][8] - JADE301, a newly nominated development candidate, is in preclinical development with a Phase 1 trial expected to start in the first half of 2027 [6][14] Upcoming Milestones - Interim results from the JADE101 Phase 1 trial are expected in the first half of 2026, which will inform dose selection for subsequent trials [7] - The Phase 2 clinical trial for JADE101 in IgA nephropathy patients is anticipated to begin mid-2026, with preliminary data expected in 2027 [6][7] - JADE201's first-in-human study is expected to begin in Q2 2026, with interim data anticipated in 2027 [14] Financial Update - As of December 31, 2025, Jade expects to report approximately $336 million in cash and equivalents, providing operational runway into the first half of 2028 [9][10]